Safety and Efficacy Results From Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (Liso-Cel) In Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

被引：0

作者：

Abramson, Jeremy ^{[1
]}

Palomba, M. Lia ^{[2
]}

Gordon, Leo ^{[3
]}

Lunning, Matthew ^{[4
]}

Wang, Michael ^{[5
]}

Arnason, Jon ^{[6
]}

Mehta, Amitkumar ^{[7
]}

Purev, Enkhtsetseg ^{[8
]}

Maloney, David ^{[9
]}

Andreadis, Charalambos ^{[10
]}

Sehgal, Alison ^{[11
]}

Solomon, Scott ^{[12
]}

Ghosh, Nilanjan ^{[13
]}

Albertson, Tina ^{[14
]}

Garcia, Jacob ^{[14
]}

Kostic, Aria ^{[14
]}

Li, Daniel ^{[14
]}

Kim, Yeonhee ^{[14
]}

Siddiqi, Tanya ^{[15
]}

机构：

[1] Massachusetts Gen Hosp, Canc Ctr, Boston, MA 02114 USA

[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[3] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA

[4] Univ Nebraska Med Ctr, Omaha, NE USA

[5] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[6] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA

[7] Univ Alabama Birmingham, Birmingham, AL USA

[8] Univ Colorado, Sch Med, Aurora, CO USA

[9] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA

[10] Univ Calif San Francisco, San Francisco, CA 94143 USA

[11] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA

[12] Northside Hosp, Canc Inst, Immunotherapy Program, Atlanta, GA USA

[13] Atrium Hlth, Levine Canc Inst, Charlotte, NC USA

[14] Juno Therapeut, Seattle, WA USA

[15] City Hope Natl Med Ctr, 1500 E Duarte Rd, Duarte, CA 91010 USA

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2020年 / 43卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

976

引用

页码：215 / 215

页数：1

共 50 条

[21] Lisocabtagene Maraleucel (Liso-Cel) in R/R MCL: Primary Analysis Results From the MCL Cohort of the Single-Arm, Multicenter, Phase I Seamless Design TRANSCEND NHL 001 Study
Palomba, M. Lia
Siddiqi, Tanya
Gordon, Leo I.
Kamdar, Manali
Lunning, Matthew
Hirayama, Alexandre V.
Abramson, Jeremy S.
Arnason, Jon
Ghosh, Nilanjan
Mehta, Amitkumar
Andreadis, Charalambos
Solomon, Scott R.
Kostic, Ana
Dehner, Christine
Espinola, Ricardo
Peng, Lily
Ogasawara, Ken
Chattin, Amy
Wang, Michael
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S458 - S458
[22] Interviews of Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) Enrolled in 2 Lisocabtagene Maraleucel (liso-cel) Trials on Their Treatment Experience for 3 Months after Infusion
Siddiqi, Tanya
Jaeger, Ulrich
Moshkovich, Olga
Braverman, Julia
Liu, Fei Fei
Lanar, Sally
Miera, Matthew
Shah, Selam
Devlen, Jennifer
Salles, Gilles
BLOOD, 2021, 138
[23] TRANSCEND: Lisocabtagene Maraleucel (liso-cel; JCAR017) Healthcare Resource Utilization in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Palomba, M. Lia
Garcia, Jacob
Wang, Lei
Dehner, Christine
Chung, Karen C.
Maloney, David G.
BLOOD, 2018, 132
[24] Multicenter, Real-World Study in Patients with R/R Large B- Cell Lymphoma (LBCL) Who Received Lisocabtagene Maraleucel (liso-cel) in the United States (US)
Crombie, Jennifer L.
Nastoupil, Loretta J.
Andreadis, Charalambos
Isufi, Iris
Hunter, Bradley
Winter, Allison
Hess, Brian
Barta, Stefan K.
Frigault, Michael J.
Palomba, Maria Lia
Grover, Natalie S.
Jain, Michael D.
Moyo, Tamara K.
Patel, Sagar S.
Pophali, Priyanka A.
Bernasconi, David
Parrilla, Charimar Santiago
Kitali, Amani
Liu, Fei Fei
Gharibo, Mecide
Pasquini, Marcelo
BLOOD, 2023, 142
[25] Impact of Lisocabtagene Maraleucel (liso-cel) Treatment on Health-Related Quality of Life and Health Utility in Patients (pts) with Relapsed/Refractory (R/R) Aggressive B Cell Non-Hodgkin Lymphoma (NHL): Transcend NHL 001
Patrick, Donald L.
Powers, Annette
Parisi, Monika
Kim, Yeonhee
Garcia, Jacob
Dehner, Christine
Maloney, David G.
BLOOD, 2019, 134
[26] TRANSCEND NHL 001: Health-related quality of life (HRQL) and symptom (Sx) impact in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) receiving lisocabtagene maraleucel (Liso-cel; JCAR017).
Patrick, Donald L.
Chung, Karen C.
Kim, Yeonhee
Garcia, Jacob
Dehner, Christine
Maloney, David G.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[27] Outreach: Results from a Phase 2 Study of Lisocabtagene Maraleucel (liso-cel) Administered As Inpatient (Inpt) or Outpatient (Outpt) Treatment in the Nonuniversity Setting in Patients (Pts) with R/R Large B-Cell Lymphoma (LBCL)
Godwin, John E.
Mattar, Bassam
Maris, Michael
Bachier, Carlos
Stevens, Don
Hoda, Daanish
Varela, Juan C.
Cherry, Mohamad
Fanning, Suzanne
Essell, James
Yimer, Habte
Courtright, Jay
Sharman, Jeff P.
Espinola, Ricardo
Mailley, Connor
Avilion, Ariel
Ogasawara, Ken
Ou, San-San
Shaughnessy, Paul
BLOOD, 2021, 138
[28] Patients (pts) with R/R large B-cell lymphoma (LBCL) treated with lisocabtagene maraleucel (liso-cel) nonconforming product (NCP) under the Expanded Access Protocol (EAP)
Till, Brian G.
Jacobson, Caron Alyce
Palomba, Maria Lia
Abramson, Jeremy S.
Arnason, Jon
Locke, Frederick L.
Caimi, Paolo Fabrizio
Grover, Natalie Sophia
Karmali, Reem
Suh, Hyung C.
Schuster, Stephen J.
Gharibo, Mecide Meric
Balint, Catherine
Rakhmawati, Trias
Jude, Veronica
Nastoupil, Loretta J.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[29] Safety and Preliminary Efficacy in Patients With Relapsed/Refractory Mantle Cell Lymphoma Receiving Lisocabtagene Maraleucel in TRANSCEND NHL 001
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (04) : 10 - 11
[30] Safety and Preliminary Efficacy in Patients with Relapsed/Refractory Mantle Cell Lymphoma Receiving Lisocabtagene Maraleucel in Transcend NHL 001
Palomba, Maria Lia
Gordon, Leo I.
Siddiqi, Tanya
Abramson, Jeremy S.
Kamdar, Manali
Lunning, Matthew A.
Maloney, David G.
Andreadis, Charalambos
Arnason, Jon E.
Ghosh, Nilanjan
Mehta, Amitkumar
Solomon, Scott R.
Farazi, Thalia
Garcia, Jacob
Dehner, Christine
Ogasawara, Ken
Gao, Jie
Wang, Michael
BLOOD, 2020, 136

← 1 2 3 4 5 →